49.24
+9.35(+23.44%)
Currency In USD
| Previous Close | 39.89 |
| Open | 41.44 |
| Day High | 49.95 |
| Day Low | 41.18 |
| 52-Week High | 65.8 |
| 52-Week Low | 2.62 |
| Volume | 827,316 |
| Average Volume | 424,797 |
| Market Cap | 311.89M |
| PE | -0.18 |
| EPS | -273.6 |
| Moving Average 50 Days | 39.07 |
| Moving Average 200 Days | 24.04 |
| Change | 9.35 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $1,313.07 as of September 30, 2025 at a share price of $49.24. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 3 years ago, it would be worth $12,371.86 as of September 30, 2025 at a share price of $49.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept i
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
GlobeNewswire Inc.
Sep 23, 2025 12:00 PM GMT
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launchesCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clin
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
GlobeNewswire Inc.
Sep 17, 2025 8:15 PM GMT
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluat